Want to see SE:VICO full AI Analyst Report?

Vicore Pharma Holding AB (VICO) Price & Analysis

3 Followers

VICO Stock Chart & Stats

kr11.08

-kr0.08(-1.06%)

At close: Mar 06 4:00 PM EST

kr11.08

-kr0.08(-1.06%)

Day’s Range― - ―

52-Week Rangekr7.35 - kr14.10

Previous CloseN/A

Volume158.42K

Average Volume (3M)520.11K

Market Cap

kr3.78B

Enterprise Valuekr2.27B

Total Cash (Recent Filing)kr1.06B

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Aug 21, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.42

Shares Outstanding281,525,600

10 Day Avg. Volume692,423

30 Day Avg. Volume520,111

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.47

Price to Sales (P/S)710.16

P/FCF Ratio-7.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr35.50

Price Target Upside220.40% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-1.71

Revenue Forecast (FY)kr883.40K

Bulls Say, Bears Say

Bulls Say

Low Debt, Strong Balance SheetReported near-zero debt and materially expanded equity give durable financial flexibility to fund clinical programs and absorb ongoing losses. This reduces refinancing risk and supports a multi-quarter runway, a critical advantage for a clinical-stage biotech dependent on financing and partnerships.

Focused AT2R Clinical PipelineA concentrated therapeutic focus on AT2R-targeted candidates for severe lung diseases, including IPF, strengthens scientific differentiation and strategic clarity. This specialization can speed trial design, make external partnering more straightforward, and concentrate R&D resources on high-potential assets.

Clinical-stage, Capital-light Operating ModelOperating as a clinical-stage developer avoids large commercial manufacturing fixed costs and distribution burdens, keeping capital intensity lower. This allows management to focus limited resources on trials and regulatory milestones, extending runway from equity and partner funding.

Bears Say

Sharp Revenue Decline & VolatilityRevenue collapsed roughly 51% in 2025 after an unusually strong 2024, reflecting unstable top-line dynamics. For a clinical-stage company, such volatility reduces visibility for planning, heightens dependence on financing events, and weakens confidence in sustainable non-dilutive funding sources.

Persistent, Worsening Cash BurnOperating cash flow has been negative every year and deteriorated materially in 2025, signaling ongoing funding needs. Continued cash burn increases dilution risk, forces reliance on capital markets or partners, and limits the firm's ability to invest flexibly or respond to setbacks in clinical development.

Deep Net Losses & Negative Returns On EquityLarge operating and net losses generate negative returns on equity across multiple years. Persistent unprofitability erodes shareholder value, limits internal funding capacity for trials, and makes the company continually dependent on external financing or strategic partnerships to sustain operations.

Vicore Pharma Holding AB News

Vicore Pharma Begins Trading ADSs on Nasdaq U.S. in Dual-Listing Move

Vicore Pharma Holding AB ( ($SE:VICO) ) has issued an update. Vicore Pharma has secured a secondary listing...

4d ago

Vicore Pharma Schedules Webcast on Buloxibutid and IPF Therapy Outlook

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an update. Vicore Pharma will host a webcast on...

1M ago

Vicore Pharma to Spotlight IPF Program at Jefferies Global Healthcare Conference

Vicore Pharma Holding AB ( ($SE:VICO) ) has shared an announcement. Vicore Pharma will present at the upcoming...

1M ago

Vicore Pharma Seeks US Dual Listing as Lead IPF Drug Nears Key Readout

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma is a Swedish clinical-stage biopharmaceutical...

1M ago

Vicore Pharma Adds Veteran Pharma Executive Peter Guenter to Board Ahead of Key IPF Milestone

An update from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma has appointed veteran...

2M ago

Vicore Pharma AGM Backs Expanded Capital Authority and New RSU Plan for Board

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an update. Vicore Pharma’s 2026 Annual General Meeting approved...

2M ago

Vicore Pharma Publishes Q1 2026 Interim Report

Vicore Pharma Holding AB ( ($SE:VICO) ) has shared an announcement. Vicore Pharma Holding AB has released its...

2M ago

Vicore Pharma to Spotlight Buloxibutid Data at 2026 ATS Meeting

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma will showcase a series of...

2M ago

Vicore Pharma Hits Early Enrollment Milestone in Key IPF Trial

Vicore Pharma Holding AB ( ($SE:VICO) ) has shared an announcement. Vicore Pharma has completed enrollment of more...

2M ago

Vicore Pharma Calls 2026 AGM With Capital and Incentive Plans on Agenda

An update from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB has...

3M ago

VICO FAQ

What was Vicore Pharma Holding AB’s price range in the past 12 months?

Vicore Pharma Holding AB lowest stock price was kr7.35 and its highest was kr14.10 in the past 12 months.

What is Vicore Pharma Holding AB’s market cap?

Vicore Pharma Holding AB’s market cap is kr3.78B.

When is Vicore Pharma Holding AB’s upcoming earnings report date?

Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 47 days.

How were Vicore Pharma Holding AB’s earnings last quarter?

Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -kr0.39 earnings per share for the quarter, beating the consensus estimate of -kr0.48 by kr0.09.

Is Vicore Pharma Holding AB overvalued?

According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vicore Pharma Holding AB pay dividends?

Vicore Pharma Holding AB does not currently pay dividends.

What is Vicore Pharma Holding AB’s EPS estimate?

Vicore Pharma Holding AB’s EPS estimate is -0.45.

How many shares outstanding does Vicore Pharma Holding AB have?

Vicore Pharma Holding AB has 281,525,600 shares outstanding.

What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?

Vicore Pharma Holding AB reported an EPS of -kr0.39 in its last earnings report, beating expectations of -kr0.48. Following the earnings report the stock price went up 6.557%.

Which hedge fund is a major shareholder of Vicore Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:VICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.

Vicore Pharma Holding AB (VICO) Earnings & Revenues

Historic Earnings Reports

VICO Stock 12 Month Forecast

Average Price Target

kr35.50

▲(220.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"kr6","39":"kr39","14.25":"kr14.25","22.5":"kr22.5","30.75":"kr30.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr35.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,14.25,22.5,30.75,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,14.073846153846155,16.067692307692308,18.06153846153846,20.055384615384618,22.049230769230768,24.043076923076924,26.03692307692308,28.03076923076923,30.024615384615387,32.01846153846154,34.012307692307694,36.00615384615385,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,13.881538461538462,15.683076923076923,17.484615384615385,19.286153846153848,21.087692307692308,22.88923076923077,24.690769230769234,26.492307692307694,28.293846153846154,30.095384615384617,31.89692307692308,33.698461538461544,{"y":35.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,13.68923076923077,15.298461538461538,16.907692307692308,18.516923076923078,20.126153846153848,21.735384615384618,23.344615384615388,24.953846153846158,26.563076923076927,28.172307692307697,29.781538461538467,31.39076923076923,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.87,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.58,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >